<DOC>
	<DOCNO>NCT00689507</DOCNO>
	<brief_summary>H9S-MC-JDCF multicenter non-randomized , single-arm , open-label , dose-escalation , dose confirmation , Phase 1 study intravenous ( IV ) LY2127399 combination bortezomib patient refractory relapse MM .</brief_summary>
	<brief_title>A Phase 1 Safety Study LY2127399 Combination With Bortezomib</brief_title>
	<detailed_description>This study drug know LY2127399 , give common treatment multiple myeloma call bortezomib ( Velcade ) . The primary purpose study ( 1 ) Determine safety LY2127399 combination bortezomib side effect might associate ; ( 2 ) Assess whether LY2127399 combination bortezomib may help patient relapsed refractory multiple myeloma ; ( 3 ) How much LY2127399 give patient along bortezomib .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Have relapse refractory multiple myeloma treat least 1 prior regimen . Prior therapy bortezomib allow relapse progression within 3 month last dose bortezomib , bortezomib consider treat physician reasonable therapy patient . Have measurable disease define one following : Monoclonal protein serum ≥1 g/dL ( 10 g/L ) . Monoclonal light chain urine protein electrophoresis ≥ 200 mg/24 hour . Involved Serum Free Light Chain ( SFLC ) level &gt; 10 mg/dL ( 100 mg/L ) provide SFLC ratio abnormal . Measurable plasmacytoma . Are ≥ 18 year age . Have give write informed consent prior studyspecific procedure Have adequate organ function include : Absolute neutrophil count ( ANC ) ≥ 1000/microliter Platelet ( PLT ) count ≥ 50,000/microliter Hemoglobin ( Hgb ) ≥ 8.0 g/dL Total bilirubin ≤ 1.5 x upper limit normal ( ULN ) ( total elevate check direct , normal , patient eligible ) Aspartate transaminase ( AST ) ≤ 3 x ULN Creatinine ≤ 3.0 mg/dl . Have performance status ≤ 2 Eastern Cooperative Oncology Group ( ECOG ) scale ( refer Attachment JDCF.5 ) . Have discontinue previous therapy cancer , include chemotherapy radiotherapy least 2 week ( 6 week mitomycinC nitrosoureas ) prior study enrollment recover acute effect therapy . Are reliable willing make available duration study willing follow study procedure . Males female reproductive potential must agree use medically approve contraceptive precaution trial 4 month follow last dose study drug . Females child bear potential must negative urine serum pregnancy test ≤ 3 day prior first dose study drug . Have estimate life expectancy ≥ 16 week . Treatment prior autologous transplant permit . If transplant use consolidation follow chemotherapy , without intervene disease progression , consider one line treatment precede chemotherapy . Have receive treatment within 30 day initial dose study drug drug receive regulatory approval indication . Have one serious preexist medical condition , opinion investigator , would preclude participation study . Have uncontrolled infection . Females pregnant lactating . Have know positive test result human immunodeficiency virus ( HIV ) , hepatitis B surface antigen ( HBSAg ) , hepatitis C antibody ( HCAb ) . Have peripheral neuropathy &gt; Grade 2 , grade pain , measure CTCAE v3.0 . Previously treat LY2127399 , significant allergy humanize monoclonal antibody , opinion investigator , pose increase risk patient . Prior allogeneic hematopoietic stem cell transplant . Prior therapy experimental agent target BAFF . Have QTc interval &gt; 450 msec baseline 12lead ECG .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Relapsed</keyword>
	<keyword>Refractory</keyword>
	<keyword>Bortezomib</keyword>
	<keyword>Velcade</keyword>
</DOC>